&Partners’s Repligen RGEN Stock Holding History

&Partners’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,445	Closed	-$237K	–	2456
2025 Q4	$237K	Buy	+1,445	New	+$226K	﹤0.01%	2050

Other funds holding RGEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

&Partners's RGEN Position: Q1 2026 in Review

&Partners sold out of Repligen (RGEN) in Q1 2026, closing a stake of 1,445 shares — an estimated $237K sold.

&Partners first reported a position in RGEN in Q4 2025 and held it in 1 quarter. The position peaked at $237K in Q4 2025. 441 funds tracked by Wall St. Rank hold RGEN as of Q1 2026.

&Partners reported no remaining Repligen position as of Q1 2026 after selling out during the quarter.
&Partners sold 1,445 Repligen shares in Q1 2026, an estimated $237K.
&Partners first reported a position in Repligen in Q4 2025 and held it in 1 quarter.
&Partners's Repligen position peaked at $237K in Q4 2025.
441 funds tracked by Wall St. Rank held Repligen as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.